Why Doesn't Mounjaro Work for Me?

The biggest misconception: that the starter dose should already be changing your weight

This is where most of the frustration comes from, and it's completely understandable. You've started treatment, you're injecting every week, and the scales aren't moving. The thing people often aren't told clearly enough is that 2.5 mg is a tolerability dose. Its purpose is to let your system settle (to reduce the likelihood of nausea and other GI effects) not to suppress appetite in any meaningful way. The medicine's appetite-reducing action becomes noticeable as the dose increases, typically from 5 mg upward.

Titration takes time. The licensed schedule moves in roughly four-week steps, meaning most people won't reach what's considered a therapeutic dose for several months. Clinical trials in the SURMOUNT programme, which involved thousands of adults, ran for 72 weeks (almost a year and a half) before the headline weight-loss figures were measured. Expecting meaningful change in the first four to eight weeks at the starter dose isn't a reasonable benchmark, even though it's a natural one to set yourself.

If you're early in treatment and feel it isn't working, the most useful thing is to speak to your prescriber before drawing conclusions. Our clinical team hear this concern regularly, and the answer is almost always the same: wait for the dose to reach a level where the medicine can actually do its job.

What else can reduce how well tirzepatide works for you

Even at higher doses, several factors can genuinely blunt the response. Diet quality matters more than people expect. Tirzepatide reduces appetite, it doesn't override the body's response to high-calorie, ultra-processed food. If calorie intake stays high despite reduced hunger signals (which can happen because appetite suppression is partial, not total), weight loss stalls. Protein intake is also worth attention; inadequate protein on a reduced-calorie diet leads to muscle loss rather than fat loss, which can slow metabolic rate over time.

Sleep and stress are underrated. Chronic sleep deprivation raises cortisol and ghrelin, hormones that drive hunger and fat storage, counteracting the medicine's effects. The same is true of sustained high stress. These aren't excuses, they're biology, and they're modifiable.

Some medicines interact with tirzepatide's mechanism or affect weight independently. Certain antidepressants, antipsychotics, corticosteroids and insulin-sensitising agents can influence weight in ways that work against the treatment. If you've started a new medicine around the same time, it's worth flagging to your prescriber. The reasons Mounjaro doesn't work for some people go beyond the dose, and identifying the right one matters before making any change.

There's also the question of injection technique and storage. Tirzepatide must be kept refrigerated at 2–8°C. A pen stored incorrectly (left in a hot car, frozen accidentally, or kept at room temperature beyond the window the Patient Information Leaflet specifies) loses potency. Injecting into the same site repeatedly can cause lipohypertrophy (a build-up of fatty tissue) that slows absorption. These are practical, fixable issues.

When it really is a reduced response, and what that means

A small proportion of people on tirzepatide do have a genuinely reduced response even at the highest tolerated dose. This is recognised in NICE's guidance on tirzepatide (TA1026): if less than 5% body weight has been lost after six months at the highest tolerated dose, the prescriber reviews whether continuing is appropriate. That's not a failure on the person's part, it reflects real biological variability in how different bodies respond to GIP and GLP-1 receptor activation.

For people in this position, the question becomes what comes next. Semaglutide (Wegovy) acts on a single receptor pathway rather than two, so the mechanism differs; some people respond better to one than the other, and that's a clinical conversation. You can read about how the tirzepatide treatment pathway works and how it's assessed if a switch is being considered.

NICE also notes that the comparison between tirzepatide and semaglutide in the SURMOUNT-5 trial (published in the New England Journal of Medicine in 2025) showed greater average weight reduction with tirzepatide at the population level. But population averages don't tell your individual story. A prescriber looking at your full clinical picture, your dose history, your lifestyle, and any other medicines you're taking is far better placed to interpret your response than a trial statistic.

A practical step if you feel stuck

Before deciding that Mounjaro doesn't work for you, it helps to ask a few honest questions. How long have you actually been at your current dose? Have there been weeks where the pen wasn't stored correctly or an injection was missed? Is something else in your life (a new medicine, a period of poor sleep, an unusually stressful few months) a plausible factor?

If the answer to those questions doesn't explain the stall, and you've been at a meaningful dose for at least 12 weeks without any progress, that's exactly the kind of situation a prescriber needs to know about. If you want to explore why tirzepatide isn't working for you in more detail, that page walks through the individual factors worth considering. For context on what others pay for private treatment while you're thinking this through, our Mounjaro cost page sets out what to expect. Otherwise, the most common questions about treatment cover many of the scenarios patients raise.

There are also related framings of this question worth reading: why Mounjaro isn't working covers the clinical perspective in more depth, and what to do when Mounjaro doesn't seem to be working looks at the practical steps. The NHS's patient information on tirzepatide is also a reliable place to check storage and missed-dose guidance directly.